Xiling Wang1, Hui Jiang2, Peng Wu3, Timothy M Uyeki4, Luzhao Feng2, Shengjie Lai2, Lili Wang5, Xiang Huo6, Ke Xu6, Enfu Chen7, Xiaoxiao Wang7, Jianfeng He8, Min Kang8, Renli Zhang9, Jin Zhang10, Jiabing Wu10, Shixiong Hu11, Hengjiao Zhang11, Xiaoqing Liu12, Weijie Fu12, Jianming Ou13, Shenggen Wu13, Ying Qin2, Zhijie Zhang1, Yujing Shi2, Juanjuan Zhang1, Jean Artois14, Vicky J Fang3, Huachen Zhu15, Yi Guan15, Marius Gilbert16, Peter W Horby17, Gabriel M Leung3, George F Gao18, Benjamin J Cowling3, Hongjie Yu19. 1. School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China. 2. Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China. 3. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China. 4. Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 5. Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China. 6. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. 7. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China. 8. Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China. 9. Shenzhen Center for Disease Control and Prevention, Shenzhen, China. 10. Anhui Provincial Center for Disease Control and Prevention, Hefei, China. 11. Hunan Provincial Center for Disease Control and Prevention, Changsha, China. 12. Jiangxi Provincial Center for Disease Control and Prevention, Nanchang, China. 13. Fujian Provincial Center for Disease Control and Prevention, Fuzhou, China. 14. Spatial Epidemiology Lab. (SpELL), 'Université Libre de Bruxelles', Brussels, Belgium. 15. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Centre of Influenza Research and State Key Laboratory of Emerging Infectious Diseases, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China; State Key Laboratory of Emerging Infectious Diseases (The University of Hong Kong-Shenzhen Branch), Shenzhen Third People's Hospital, Shenzhen, China; Shantou University-The University of Hong Kong Joint Institute of Virology, Shantou University, Shantou, China. 16. Spatial Epidemiology Lab. (SpELL), 'Université Libre de Bruxelles', Brussels, Belgium; Fonds National de la Recherche Scientifique, Brussels, Belgium. 17. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK. 18. Chinese Center for Disease Control and Prevention, Beijing, China; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. 19. School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China. Electronic address: cfetpyhj@vip.sina.com.
Abstract
BACKGROUND: The avian influenza A H7N9 virus has caused infections in human beings in China since 2013. A large epidemic in 2016-17 prompted concerns that the epidemiology of the virus might have changed, increasing the threat of a pandemic. We aimed to describe the epidemiological characteristics, clinical severity, and time-to-event distributions of patients infected with A H7N9 in the 2016-17 epidemic compared with previous epidemics. METHODS: In this epidemiological study, we obtained information about all laboratory-confirmed human cases of A H7N9 virus infection reported in mainland China as of Feb 23, 2017, from an integrated electronic database managed by the China Center for Disease Control and Prevention (CDC) and provincial CDCs. Every identified human case of A H7N9 virus infection was required to be reported to China CDC within 24 h via a national surveillance system for notifiable infectious diseases. We described the epidemiological characteristics across epidemics, and estimated the risk of death, mechanical ventilation, and admission to the intensive care unit for patients admitted to hospital for routine clinical practice rather than for isolation purpose. We estimated the incubation periods, and time delays from illness onset to hospital admission, illness onset to initiation of antiviral treatment, and hospital admission to death or discharge using survival analysis techniques. FINDINGS: Between Feb 19, 2013, and Feb 23, 2017, 1220 laboratory-confirmed human infections with A H7N9 virus were reported in mainland China, with 134 cases reported in the spring of 2013, 306 in 2013-14, 219 in 2014-15, 114 in 2015-16, and 447 in 2016-17. The 2016-17 A H7N9 epidemic began earlier, spread to more districts and counties in affected provinces, and had more confirmed cases than previous epidemics. The proportion of cases in middle-aged adults increased steadily from 41% (55 of 134) to 57% (254 of 447) from the first epidemic to the 2016-17 epidemic. Proportions of cases in semi-urban and rural residents in the 2015-16 and 2016-17 epidemics (63% [72 of 114] and 61% [274 of 447], respectively) were higher than those in the first three epidemics (39% [52 of 134], 55% [169 of 306], and 56% [122 of 219], respectively). The clinical severity of individuals admitted to hospital in the 2016-17 epidemic was similar to that in the previous epidemics. INTERPRETATION: Age distribution and case sources have changed gradually across epidemics since 2013, while clinical severity has not changed substantially. Continued vigilance and sustained intensive control efforts are needed to minimise the risk of human infection with A H7N9 virus. FUNDING: The National Science Fund for Distinguished Young Scholars.
BACKGROUND: The avian influenza A H7N9 virus has caused infections in human beings in China since 2013. A large epidemic in 2016-17 prompted concerns that the epidemiology of the virus might have changed, increasing the threat of a pandemic. We aimed to describe the epidemiological characteristics, clinical severity, and time-to-event distributions of patients infected with A H7N9 in the 2016-17 epidemic compared with previous epidemics. METHODS: In this epidemiological study, we obtained information about all laboratory-confirmed human cases of A H7N9 virus infection reported in mainland China as of Feb 23, 2017, from an integrated electronic database managed by the China Center for Disease Control and Prevention (CDC) and provincial CDCs. Every identified human case of A H7N9 virus infection was required to be reported to China CDC within 24 h via a national surveillance system for notifiable infectious diseases. We described the epidemiological characteristics across epidemics, and estimated the risk of death, mechanical ventilation, and admission to the intensive care unit for patients admitted to hospital for routine clinical practice rather than for isolation purpose. We estimated the incubation periods, and time delays from illness onset to hospital admission, illness onset to initiation of antiviral treatment, and hospital admission to death or discharge using survival analysis techniques. FINDINGS: Between Feb 19, 2013, and Feb 23, 2017, 1220 laboratory-confirmed human infections with A H7N9 virus were reported in mainland China, with 134 cases reported in the spring of 2013, 306 in 2013-14, 219 in 2014-15, 114 in 2015-16, and 447 in 2016-17. The 2016-17 A H7N9 epidemic began earlier, spread to more districts and counties in affected provinces, and had more confirmed cases than previous epidemics. The proportion of cases in middle-aged adults increased steadily from 41% (55 of 134) to 57% (254 of 447) from the first epidemic to the 2016-17 epidemic. Proportions of cases in semi-urban and rural residents in the 2015-16 and 2016-17 epidemics (63% [72 of 114] and 61% [274 of 447], respectively) were higher than those in the first three epidemics (39% [52 of 134], 55% [169 of 306], and 56% [122 of 219], respectively). The clinical severity of individuals admitted to hospital in the 2016-17 epidemic was similar to that in the previous epidemics. INTERPRETATION: Age distribution and case sources have changed gradually across epidemics since 2013, while clinical severity has not changed substantially. Continued vigilance and sustained intensive control efforts are needed to minimise the risk of human infection with A H7N9 virus. FUNDING: The National Science Fund for Distinguished Young Scholars.
Authors: Benjamin J Cowling; Lianmei Jin; Eric H Y Lau; Qiaohong Liao; Peng Wu; Hui Jiang; Tim K Tsang; Jiandong Zheng; Vicky J Fang; Zhaorui Chang; Michael Y Ni; Qian Zhang; Dennis K M Ip; Jianxing Yu; Yu Li; Liping Wang; Wenxiao Tu; Ling Meng; Joseph T Wu; Huiming Luo; Qun Li; Yuelong Shu; Zhongjie Li; Zijian Feng; Weizhong Yang; Yu Wang; Gabriel M Leung; Hongjie Yu Journal: Lancet Date: 2013-06-24 Impact factor: 79.321
Authors: Ying Qin; Peter W Horby; Tim K Tsang; Enfu Chen; Lidong Gao; Jianming Ou; Tran Hien Nguyen; Tran Nhu Duong; Viktor Gasimov; Luzhao Feng; Peng Wu; Hui Jiang; Xiang Ren; Zhibin Peng; Sa Li; Ming Li; Jiandong Zheng; Shelan Liu; Shixiong Hu; Rongtao Hong; Jeremy J Farrar; Gabriel M Leung; George F Gao; Benjamin J Cowling; Hongjie Yu Journal: Clin Infect Dis Date: 2015-05-04 Impact factor: 9.079
Authors: J S Malik Peiris; Benjamin J Cowling; Joseph T Wu; Luzhao Feng; Yi Guan; Hongjie Yu; Gabriel M Leung Journal: Lancet Infect Dis Date: 2015-12-02 Impact factor: 25.071
Authors: Eric H Y Lau; C Agnes Hsiung; Benjamin J Cowling; Chang-Hsun Chen; Lai-Ming Ho; Thomas Tsang; Chiu-Wen Chang; Christl A Donnelly; Gabriel M Leung Journal: BMC Infect Dis Date: 2010-03-06 Impact factor: 3.090
Authors: Dennis K M Ip; Qiaohong Liao; Peng Wu; Zhancheng Gao; Bin Cao; Luzhao Feng; Xiaoling Xu; Hui Jiang; Ming Li; Jing Bao; Jiandong Zheng; Qian Zhang; Zhaorui Chang; Yu Li; Jianxing Yu; Fengfeng Liu; Michael Y Ni; Joseph T Wu; Benjamin J Cowling; Weizhong Yang; Gabriel M Leung; Hongjie Yu Journal: BMJ Date: 2013-06-24
Authors: Marius Gilbert; Nick Golding; Hang Zhou; G R William Wint; Timothy P Robinson; Andrew J Tatem; Shengjie Lai; Sheng Zhou; Hui Jiang; Danhuai Guo; Zhi Huang; Jane P Messina; Xiangming Xiao; Catherine Linard; Thomas P Van Boeckel; Vincent Martin; Samir Bhatt; Peter W Gething; Jeremy J Farrar; Simon I Hay; Hongjie Yu Journal: Nat Commun Date: 2014-06-17 Impact factor: 14.919
Authors: Jørgen de Jonge; Harry van Dijken; Femke de Heij; Sanne Spijkers; Justin Mouthaan; Rineke de Jong; Paul Roholl; Eduardo Alfredo Adami; Milena Apetito Akamatsu; Paulo Lee Ho; Livia Brunner; Nicolas Collin; Martin Friede; José A Ferreira; Willem Luytjes Journal: NPJ Vaccines Date: 2020-05-11 Impact factor: 7.344